Oruka Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Oruka Therapeutics (ORKA).

Price Target Range — 9 Quarters

Analyst Consensus — 15 Analysts

15Buy

Consensus RatingBuy# Analysts15Avg. Consensus PT$87Upside to Avg. PT+3.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Wedbush	Martin Fan	Maintained	Outperform	$165
Sep 24, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$120
Sep 3, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$120
Aug 11, 2026	Guggenheim	Yatin Suneja	Maintained	Buy	$200
Aug 11, 2026	Wedbush	Martin Fan	Maintained	Outperform	$165
Aug 11, 2026	BTIG	Julian Harrison	Maintained	Buy	$151
Aug 3, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$120
Jul 13, 2026	BTIG	Julian Harrison	Maintained	Buy	$151
Jul 1, 2026	UBS	Michael Yee	PT Raise	Buy	$100→$130
Jun 23, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$120
May 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$120
May 14, 2026	BTIG	Julian Harrison	Maintained	Buy	$151
Apr 29, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$75→$120
Apr 28, 2026	UBS	Michael Yee	PT Raise	Buy	$75→$100
Apr 28, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$78→$160
Apr 27, 2026	BTIG	Julian Harrison	PT Raise	Buy	$78→$151
Apr 15, 2026	Wedbush	Martin Fan	PT Raise	Outperform	$45→$85
Apr 13, 2026	Guggenheim	Yatin Suneja	Maintained	Buy	$125
Apr 13, 2026	BTIG	Julian Harrison	PT Raise	Buy	$73→$78
Apr 13, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$40→$70

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.

Benzinga Newsdesk

Oruka Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Oruka Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

PRO
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

PRO
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

People Also Watch

People Also Watch

Oruka Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Oruka Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

PROHC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

PROHC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

PROGuggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

PROBTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

PROHC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

People Also Watch

People Also Watch

PRO
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

PRO
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

PRO
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target